Drug updated on 5/17/2024

Dosage FormInjection (subcutaneous; 150mg/mL)
Drug ClassInterleukin-13 antagonists
Ongoing and
Completed Studies


  • Indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.

Latest News

loading GIF

This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Adbry (Tralokinumab-ldrm) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. It can be used with or without topical corticosteroids.
  • The information comes from 17 systematic reviews and meta-analyses, focusing on direct outcomes such as efficacy, safety, and specific subpopulation considerations where available.
  • In terms of efficacy comparison to other drugs like Dupilumab and JAK inhibitors (Janus kinase inhibitors), tralokinumab shows similar effectiveness when combined with topical corticosteroids. However, JAK inhibitors were generally associated with higher efficacy but also a higher incidence of Herpes zoster.
  • Safety comparisons reveal that tralokinumab has no significant difference observed in the incidence of overall adverse events compared to placebo. Yet, it was found safer than JAK inhibitors which showed a dose-dependent increase in Herpes zoster occurrence.
  • Tralokinumab was associated with an increased incidence of conjunctivitis compared to placebo; however, this condition was mostly mild or moderate and transient - similar findings were noted for Dupilumab and other IL13-inhibitors.
  • Compared to systemic treatments like JAK inhibitors known for harmful outcomes due to increased adverse events, both tralokinumab-ldrm (Adbry) & dupilumab have been listed among biologics having favorable safety profiles despite modestly increasing the risk towards conjunctivitis.
  • The studies predominantly focused on adult populations suffering from moderate-to-severe AD, indicating sustained/improved efficiency/safety over time, including up till 52 weeks into treatment.
  • Few studies addressed pediatric use directly, thus highlighting the need for further research, especially concerning long-term safety/efficiency aspects related to biologics usage such as tralokinumab within children.

Product Monograph / Prescribing Information

Document TitleYearSource
Adbry (tralokinumab-ldrm) Prescribing Information.2022LEO Pharma Inc., Madison, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. 2024British Journal of Dermatology
Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis.2024Postepy Dermatologii i Dlergologii
Matching-adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis.2024Dermatology and Therapy
Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. 2023Journal of Allergy and Clinical Immunology
Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. 2023Medicine
Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.2023Heliyon
Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: Pooled data from two phase iii trials2023American Journal of Clinical Dermatology
Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis.2023Dermatology and Therapy
The efficacy and safety of IL-13 inhibitors in atopic dermatitis: a systematic review and meta-analysis.2022Frontiers in Immunology
Systemic immunomodulatory treatments for atopic dermatitis: Update of a living systematic review and network meta-analysis.2022JAMA Dermatology
Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis. 2022Acta Dermato-venereologica
Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: Results from five tralokinumab clinical trials.2022The British Journal of Dermatology
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.2021Journal of The European Academy of Dermatology and Venereology
Biological Therapies for Atopic Dermatitis: A Systematic Review.2021Dermatology
Systemic treatments for eczema: a network meta-analysis.2020The Cochrane Database of Systematic Reviews
Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: a systematic review.2020Clinical & Experimental Allergy
Relative efficacy of systemic treatments for atopic dermatitis.2019Journal of the American Academy of Dermatology

Clinical Practice Guidelines